This site is for U.S. Healthcare Professionals only.
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
Poster
Other/Multi
ASCO 2025 | May 30-June 3,2025
A phase 1, first-in-human study of DS-2243, an HLA-A*02/NY-ESO–directed bispecific T‑cell engager, in patients with advanced solid tumors
Poster
T-DXd
ESMO Asia 2024 | December 6-8, 2024
An open-label, multicenter, phase 2 study of trastuzumab deruxtecan (T-DXd) in patients with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) Part 2
Poster
T-DXd
AACR 2025 | April 25-29, 2025
Baseline serum protein analysis of patients with interstitial lung disease/pneumonitis (ILD) in 3 trastuzumab deruxtecan (T-DXd) trials: DESTINY-Breast01, DESTINY-Breast04, and DESTINY-Lung01
Oral
Pipeline Compounds
ESMO 2025 | October 17-21, 2025
DS-3939, a tumor-associated mucin 1 (TA-MUC1)–directed antibody–drug conjugate, in patients with advanced/metastatic solid tumors: Initial results from a first-in-human study
Poster
Valemetostat
ASCPT 2025 | May 28-31, 2025
Effect of valemetostat on the pharmacokinetics of midazolam and digoxin (CYP3A and P-gp substrates): A phase 1 drug–drug interaction study in patients with refractory or relapsed non-hodgkin lymphoma
Poster
I-DXd
ASCO 2025 | May 30-June 3,2025
KEYMAKER-U06 Substudy O6E: A phase 1/2 open-label, umbrella platform study of ifinatamab deruxtecan in combination with pembrolizumab with or without chemotherapy for first-line treatment of advanced esophageal squamous cell carcinoma
Oral
Dato-DXd, T-DXd, Valemetostat
AACR 2025 | April 25-29, 2025
Preclinical assessment of valemetostat, a dual inhibitor of EZH2 and EZH1, combined with trastuzumab deruxtecan and datopotamab deruxtecan for multiple solid tumors
Poster
Quizartinib
COSTEM 2024 | October 24-27, 2024
QuANTUM-First Trial: FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)–specific measurable residual disease (MRD) clearance assessed through induction and consolidation is associated with improved overall survival in newly diagnosed FLT3-ITD+ AML patients
Poster
Quizartinib
COSTEM 2024 | October 24-27, 2024
QuANTUM-First: Safety by treatment phase and by age in newly diagnosed patients with FMS-like tyrosine kinase 3–internal tandem duplication (FLT3-ITD) positive acute myeloid leukemia
Poster
T-DXd
ESMO Asia 2024 | December 6-8, 2024
Randomized, open-label, multicenter, phase 3 study of trastuzumab deruxtecan (T-DXd) with rilvegostomig vs standard of care (SOC) in first-line, human epidermal growth factor receptor 2 (HER2)-expressing, locally advanced or metastatic (LA/m) biliary tract cancer (BTC): DESTINY-BTC01
Pages:
1 2